Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
Sodium alginate; Potassium hydrogen carbonate
Reckitt Benckiser Ireland Ltd
A02BX; A02BX13
Sodium alginate; Potassium hydrogen carbonate
1000/200 milligram(s)
Oral suspension
Product not subject to medical prescription
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD); alginic acid
Not marketed
2004-03-05
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Gaviscon Advance Peppermint Oral Suspension Sachets sodium alginate 500 mg potassium hydrogen carbonate 100 mg READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always us this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. • Keep this leaflet. You may need to read it again • Ask your pharmacist if you need more information or advice • If you get any side-effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • You must talk to a doctor if you do not feel better or if you feel worse after 7 days. WHAT IS IN THIS LEAFLET: 1. What Gaviscon Advance Sachets are and what they are used for 2. What you need to know before you take Gaviscon Advance Sachets 3. How to take Gaviscon Advance Sachets 4. Possible side effect 5. How to store Gaviscon Advance Sachets 6. Contents of the pack and other information 1. WHAT GAVISCON ADVANCE SACHETS ARE AND WHAT THEY ARE USED FOR This product belongs to a group of medicines called “reflux suppressants”. This product forms a protective layer that floats on top of the stomach contents. This layer prevents reflux and keeps the stomach contents away from the lining of the food pipe to relieve the symptoms of heartburn and acid indigestion. This medicine is used for the treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy, or in patients with symptoms related to reflux oesophagitis. You must talk to a doctor if you do not feel better or if you feel worse after 7 days. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE GAVISCON ADVANCE SACHETS DO NOT TAKE GAVISCON ADVANCE SACHETS: • if you know you are allergic to any of the ingredients (listed in section 6). WARNINGS AND PRECAUTIONS THIS MEDICINE CONTAINS 57.85 MG SODIUM Belgenin tamamını okuyun
Health Products Regulatory Authority 09 February 2023 CRN00DC3L Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gaviscon Advance Peppermint Oral Suspension Sachets Sodium Alginate 500mg, Potassium hydrogen carbonate 100 mg Oral suspension. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml dose contains sodium alginate 500 mg and potassium hydrogen carbonate 100 mg. Excipients with known effect: Methylparahydroxybenzoate (E218) (20 mg / 5 ml) Propylparahydroxybenzoate (E216) (3 mg / 5 ml) Sodium (57.85 mg / 5 ml) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension. Off-white viscous suspension in sachets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals, or during pregnancy, or in patients with symptoms related to reflux oesophagitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Adults and children 12 years and over: 5-10 ml after meals and at bedtime. Children under 12 years: Should be given only on medical advice. DURATION OF TREATMENT: If symptoms do not improve after seven days, the clinical situation should be reviewed. SPECIAL PATIENT GROUPS: Elderly: No dose modification is required for this age group. Hepatic Impairment: No modifications necessary. Renal Insufficiency: Caution if highly restricted salt diet is necessary (see section 4.4). METHOD OF ADMINISTRATION For oral use. Any unused solution should be discarded. Health Products Regulatory Authority 09 February 2023 CRN00DC3L Page 2 of 4 4.3 CONTRAINDICATIONS This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients listed in section 6.1 including methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) (see section 4.4). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE If symptoms do not improve after seven days, the clinic Belgenin tamamını okuyun